BridgeBio Pharma Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
BBIO$78.67+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | 139 |
| Consolidated Balance Sheets as of December 31, 2023 and December 31, 2022 | 142 |
| Consolidated Statements of Operations for each of the three years in the period ended December 31, 2023 | 143 |
| Consolidated Statements of Comprehensive Loss for each of the three years in the period ended December 31, 2023 | 144 |
| Consolidated Statements of Redeemable Convertible Noncontrolling Interests and Stockholders’ Equity (Deficit) for each of the three years in the period ended December 31, 2023 | 145 |
| Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2023 | 146 |
| Notes to Consolidated Financial Statements | 148 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.